Retired man’s battle with terminal cancer aided by Ivermectin use

Retired sawmill worker Rick Alderson faced a grim prognosis in November 2020 when diagnosed with terminal colon cancer, which quickly metastasised to his liver.

Despite being initially deemed too advanced for treatment, Alderson and his wife, Eve, turned to faith and decided to pursue all possible treatments. Beginning with radiation therapy and followed by chemotherapy, Alderson’s situation seemed dire, especially after his cancer markers, specifically carcinoembryonic antigen (CEA) levels, alarmingly increased.

Amidst the COVID-19 pandemic, Alderson discovered Ivermectin, a drug with reported potential in boosting the effectiveness of conventional cancer treatments. Health experts decried the medication as a ‘horse de-wormer’, despite two scientists winning the 2015 Nobel Prize in Medicine for their research on the off-patent medication, which is also included on the World Health Organisation’s ‘Essential Medicines’ list as an ‘anti-infective’ treatment.

Deciding to integrate Ivermectin into his regimen in February 2021 led to a dramatic and rapid decrease in his CEA levels and a significant reduction in liver tumors, from 25 to just three.

Alderson lived an additional two years, surpassing his initial six-month life expectancy. Eve Alderson credited ivermectin and the chemotherapy drug fluorouracil for extending her husband’s life, saying it had ‘an instrumental role in his treatment’. The case has shed light on the broader potential of Ivermectin as an anti-cancer agent, backed by oncological research and individual anecdotes alike.

Research on Ivermectin’s anti-cancer properties dates back to 1995, which has shown its capability to reverse drug resistance in tumors, target cancer stem cells, and enhance the effects of chemotherapy and radiation. Though primarily recognised for its anti-parasitic uses, its broad impact on the immune system and inhibition of cancer cell cycles present a promising adjunct to conventional cancer treatments.

Despite the promising outcomes in Alderson’s case and others, the medical community urges caution, noting that ivermectin’s efficacy as a standalone treatment for cancer remains unproven, with ongoing research aimed at integrating it with existing therapies. Clinical trials and further studies are essential to understand its full potential and application in oncology.